Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2020-10-23 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - U.S. FDA GRANTED BREAKTHROUGH THERAPY DESIGNATION TO ANTI-PD-L1 ANTIBODY SUGEMALIMAB FOR THE TREATMENT OF ADULT PATIENTS WITH R/R ENKTL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the U.S. FDA granting Breakthrough Therapy Designation to their drug sugemalimab. It contains detailed information about the drug, clinical trial data, regulatory status, and company background. There are no financial statements, quarterly or annual results, or management discussion of financial performance. The document is not a report but an announcement of a regulatory milestone and clinical development update. It is not a certification or a voting result announcement. The length is 8510 characters, which is substantial but the content is clearly an announcement of a regulatory and clinical development event. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2020-10-23 English
ANNOUNCEMENT ON THE UNAUDITED MAJOR OPERATIONAL DATA OF THE THIRD QUARTER OF 2020
Regulatory Filings Classification · 95% confidence The document is an announcement from Yanzhou Coal Mining Company Limited presenting unaudited major operational data for the third quarter of 2020. It includes production and sales volumes for coal and coal chemicals, with comparisons to previous periods. The document explicitly states that the data is preliminary and unaudited, and it is a voluntary announcement rather than a full financial report. The length is short (2879 characters), and it does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). It is not an earnings release (ER) since it provides operational data rather than key financial highlights. It is also not a full Annual Report (10-K) or Audit Report (AR). The document is a regulatory announcement of operational data, fitting best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2020-10-19 English
PUBLICATION OF THE PRODUCTION AND SALES VOLUME FOR THE THIRD QUARTER OF 2020 OF AN OVERSEAS SUBSIDIARY CONTROLLED BY YANZHOU COAL MINING COMPANY LIMITED
Capital/Financing Update Classification · 85% confidence The document is a voluntary announcement by Yanzhou Coal Mining Company Limited regarding the production and sales volume for the third quarter of 2020 of an overseas subsidiary, Yancoal Australia. It provides summary data on coal production and sales volumes but does not contain comprehensive financial statements or detailed financial analysis. The document is relatively short (2469 characters) and refers readers to the full reports published by Yancoal Australia on the ASX and HKEX websites for further details. This indicates that the document is an announcement of operational data rather than a full interim or quarterly report. It is not a full financial report (like an Interim/Quarterly Report) because it lacks substantive financial data and analysis. It is also not a Regulatory Filing or Report Publication Announcement since it contains actual data rather than just a notice of report availability. The content fits best with a Capital/Financing Update (CAP) or Earnings Release (ER) category. However, since it focuses on production and sales volume rather than earnings or financial results highlights, it is more aligned with a Capital/Financing Update type of announcement about operational metrics. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-10-19 English
VOLUNTARY ANNOUNCEMENT - U.S. FDA GRANTED ORPHAN DRUG DESIGNATION TO ANTI-PD-L1 ANTIBODY SUGEMALIMAB FOR THE TREATMENT OF T-CELL LYMPHOMA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the U.S. FDA granting orphan drug designation to their anti-PD-L1 antibody sugemalimab for the treatment of T-cell lymphoma. It contains detailed information about the drug, clinical studies, and company background. There are no financial statements, earnings data, or regulatory filings such as 10-K or interim reports. The document is not a report itself but an announcement of a regulatory milestone related to drug development. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a voluntary announcement about a regulatory and clinical development event, which aligns best with the Regulatory Filings (RNS) category as a general regulatory announcement that does not fit other specific categories.
2020-10-19 English
NOTIFICATION OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a notification of a board meeting scheduled to consider the publication of the company's unaudited third quarterly results. It is an announcement about an upcoming event rather than the actual financial report or detailed results. The document length is short (1641 characters), and it does not contain any financial data or analysis itself. According to the rules, such announcements about meetings to discuss financial results are best classified as Regulatory Filings (RNS) because they do not contain the report itself nor detailed financial information.
2020-10-12 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2020-10-12 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.